Revenue segments as reported by the company.

Cannabis revenue

Distribution revenue

Beverage alcohol revenue

Wellness revenue

Adult-use

Canada - Medical

International - Medical

Bulk

Hemp

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Impairment of Assets

Litigation settlement

Transaction costs

Change in fair value of contingent consideration

Restructuring costs

Other than temporary change in fair value of convertible notes receivable

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Tilray Brands

Tilray Brands, Inc. is a global cannabis-lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia, and Latin America. The firm is focused on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. Its products include dried cannabis and cannabis extracts. It operates through the following segments: Cannabis and Hemp. The Cannabis segment consists of adult-use, medical and bulk sales of cannabis under regulated licenses and sold to retail, wholesale, pharmacy, government, and direct to patient. The Hemp segment consists of hemp seed, hemp foods, and broad spectrum hemp extract containing CBD, which are sold in an unlicensed operation and sold to retail, wholesale and direct to consumers. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Earnings data Q1 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Tilray Brands reports record revenue and optimistic outlook for 2025

Tilray Brands achieved remarkable financial performance in Q4 2024, driven by strategic acquisitions and a focus on innovation. Despite challenges like price compression, the company remains optimistic about future growth opportunities. Tilray's commitment to quality products and innovation positions it well for continued success in the market.

Tilray Brands reports record Q1 revenue growth and global expansion

Tilray Brands delivered a robust performance in Q1 2025, showcasing strong revenue growth, margin improvement, and strategic expansion across its diversified product portfolio.
While facing challenges in a competitive landscape and evolving regulatory environment, Tilray's financial strength, international growth initiatives, and focus on innovation position it well for future success.
By capitalizing on opportunities in wellness products, expanding into new beverage categories, and leveraging strategic partnerships, Tilray is poised for continued growth and market leadership.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Tilray Brands, Inc. is a global cannabis-lifestyle and consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis Business, Distribution Business, Beverage Alcohol Business, and Wellness Business. The Cannabis Business segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution Business segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage Alcohol Business segment refers to the production, marketing, and sale of beverages. The Wellness Business segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Canopy Growth

Curaleaf Holdings, Inc.

PayPal

Trulieve Cannabis Corp.

Tesla

The cannabis industry operates in a quasi-legal environment that makes it difficult for companies to grow. The federal ban on pot creates many hurdles for businesses.

Is Elon Musk the Hero the Cannabis Industry Needs Right Now?

CANTANHEDE, Portugal, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Tilray Medical, a division of Tilray Brands, Inc. ("Tilray" or the "Company") (Nasdaq: TLRY; TSX: TLRY) and a global leader in medical cannabis, empowering the therapeutic alliance between patients and healthcare practitioners to make informed individualized health decisions, transforming healthcare, today announced their contribution to an independent clinical trial to research the efficacy of medical cannabis as a treatment for glioblastoma, a severe form of brain cancer. The clinical trial will be conducted in Spain, recruiting 30 patients from eight specialized neuro-oncology medical sites, in partnership with renowned scientists from the Spanish Research Group of Neuro-Oncology (GEINO) and the Complutense University of Madrid, with Tilray Medical providing the pharmaceutical-grade medical cannabis for the trial (THC/CBD 1:1) for administration to patients. The trial is funded by the Medical Cannabis Bike Tour Foundation charity and is scheduled to commence at University Hospital 12 de Octubre, on September 5, 2023.

Tilray Medical Supports New Clinical Trial to Study Medical Cannabis in Glioblastoma Cancer Treatment

Bitfarms Ltd

Kinross Gold

Solid Power

Standard Lithium Ltd

Every investor dreams of making millions from the markets. And that dream is realistic with a proper investment strategy and patience.

7 Penny Stocks To Make You The Millionaire Next Door: October Edition

Tilray (NASDAQ: TLRY) stock price has erased most of the gains it made in September as hopes of regulatory clarity rose. After surging to $3.40 on September 5th, the cannabis stock has plunged by ~41% and is now at its lowest level since July 27th.

Tilray stock price forecast: TLRY could crash by ~25% soon

AFC Gamma

Green Thumb Industries Inc.

Innovative Industrial Properties

Amplify Alternative Harvest ETF

NewLake Capital Partners, Inc.

Global X Cannabis ETF

Cannabis stocks may be one of the most controversial trades on the market. But it could also turn out to be one of the most profitable.

Green Gold Rush: Top 7 Cannabis Stocks Primed for Explosive Growth

Inspired by Montauk's Best-Selling Beer, Major Wave Chaser Will Quench Growing Thirst for Full Flavors and High Alcohol Inspired by Montauk's Best-Selling Beer, Major Wave Chaser Will Quench Growing Thirst for Full Flavors and High Alcohol

Montauk Releases Major Wave Chaser Double India Pale Ale

Tilray's short interest has reached a new 52-week high, indicating growing skepticism and concerns over the company's financial situation. The number of outstanding shares has significantly increased due to dilution, leading to frustration among investors. Tilray's recent financial results were mixed, but the acquisition of beer brands has diversified its revenue base and led to rising revenue estimates.

Tilray Shorts Surge On More Dilution

Aurora Cannabis

Cannabis companies in Canada have been struggling to gain market share. Competition is fierce, and growth rates have deteriorated significantly in recent years.

Canada Legalized Marijuana 5 Years Ago. Why Is the Industry Now in Such Bad Shape?

Tilray's marijuana business is still unprofitable. Its alcohol segment is a rising star.

3 Key Metrics to Watch for Tilray Stock

SNDL Inc.

Tilray Brands has been hampered in realizing its multinational marijuana ambitions. SNDL is gaining strength in Canada, but the competition might be a problem.

Better Turnaround Stock: Tilray Brands vs. SNDL

Tilray Brands (TLRY) posts wider-than-expected loss per share in first-quarter fiscal 2024.

Tilray Brands (TLRY) Q1 Loss Wider, Revenues Increase Y/Y

Cronos Group

Unsurprisingly, the current year has been depressing for cannabis stocks. Regulatory headwinds continue to play spoilsport and making stock predictions somewhat difficult.

3 Cannabis Stocks Looking Hot Heading Into 2024

Tilray announced record quarterly revenue led by cannabis segment sales. Profits technically fell short of expectations, hurt by acquisition costs and a wholesale cannabis transaction aimed at normalizing inventory levels.

Tilray's Cannabis Business Leads the Way (for Now) as Losses Narrow

Tilray (NASDAQ: TLRY ) is headquartered in Canada, but TLRY stock would certainly benefit from federal-level cannabis decriminalization in the U.S. This type of legislative reform won't happen overnight, however. It's still fine to hold a small stake in TLRY stock, but be realistic with your expectations and consider extending your investment timeline.

2024 Cannabis Pick: Hold Tilray Stock for Years, Not Months

If rate cuts are indeed a big catalyst, the outlook for equities is bullish for the next year and 2025. Consultancy firm Capital Economics believes that the S&P 500 Index can touch 6,500 in 2025 with artificial intelligence stocks likely to be the market upside drivers.

3 Penny Stocks to Buy for 10-Bagger Returns by 2025

Tilray Inc (NASDAQ: TLRY) is well-positioned even if cannabis is not fully legalised in the United States, as per its Chief Executive – Irwin Simon. Tilray has diversified its growth opportunities A federal approval will sure serve as a strong catalyst for Tilray.

Tilray CEO: we'll do fine even without the U.S. legalisation

Cannabis producer Tilray Brands Inc. reported first-quarter earnings that beat expectations as it expands its portfolio

Tilray Brands revenue jumps, losses narrow as it pivots away from cannabis

Tilray Brands, Inc. (NASDAQ:TLRY ) Q1 2024 Earnings Conference Call October 4, 2023 8:30 AM ET Company Participants Berrin Noorata - Chief Corporate Affairs and Communications Officer Irwin Simon - Chairman and Chief Executive Officer Carl Merton - Chief Financial Officer Blair MacNeil - President, Tilray Canada Denise Faltischek - Chief Strategy Officer and Head of International Ty Gilmore - President, U.S. Beer Conference Call Participants Robin Holby - TD Cowen Andrew Carter - Stifel Aaron Grey - Alliance Global Partners Matt Bottomley - Canaccord Genuity Frederico Gomes - ATB Capital Markets Michael Lavery - Piper Sandler Bill Kirk - ROTH MKM John Zamparo - CIBC Operator Thank you for joining today's conference call to discuss Tilray Brands, Inc. Financial Results for the 2024 Fiscal First Quarter ended August 31, 2023. All lines have been placed on mute to prevent any background noise.

Tilray Brands, Inc. (TLRY) Q1 2024 Earnings Call Transcript

Tilray (NASDAQ: TLRY ) stock is on the move Wednesday as investors react to the company's earnings report for its fiscal first quarter of 2024. Tilray's revenue of $176.95 million initially saw shares of TLRY stock rise higher this morning.

Why Is Tilray (TLRY) Stock Down 4% Today?

The headline numbers for Tilray Brands, Inc. (TLRY) give insight into how the company performed in the quarter ended August 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Tilray Brands, Inc. (TLRY) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Tilray Brands, Inc. (TLRY) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.08 per share a year ago.

Tilray Brands, Inc. (TLRY) Reports Q1 Loss, Tops Revenue Estimates

Tilray Inc (NASDAQ:TLRY) shares rose in pre-market trading Wednesday after the New York and Leamington, Ontario-based cannabis and consumer packaged goods (CPG) company reported first quarter fiscal 2024 results that surpassed expectations. It traded up 6.3% at US$2.38 shortly before the opening bell in New York.

Tilray Brands narrows net loss and grows Canadian cannabis market share in 1Q

Tilray Brands Inc. stock rose 2.7% in premarket trades on Wednesday after it reported a wider-than-expected loss and beat its revenue target as the cannabis company maintained its leading position in Canada and diversified into beer in its fiscal first quarter.

Tilray's net loss narrows as revenue climbs to record

Record Q1 Net Revenue of $177 Million, Representing 15% Growth Year over Year Increased #1 Cannabis Market Share Position in Canada to 13.4% Grew Canadian Cannabis Revenue by 16.5% and International Cannabis Revenue by 37% With Closing of Acquisition of Eight Craft Beer and Beverage Brands, Creating 5 th Largest U.S. Craft Beer Brewer with 5% Market Share in Growing Craft Market Conference Call to be Held at 8:30 a.m. ET Today NEW YORK and LEAMINGTON, Ontario, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (“Tilray”, “our”, “we” or the “Company”) (Nasdaq: TLRY; TSX: TLRY), a leading global cannabis-lifestyle and consumer packaged goods company, today reported financial results for its first quarter fiscal year 2024 ended August 31, 2023.

Tilray Brands Reports Q1 2024 Financial Results

Amdocs

Li Auto Inc.

By investing in blue-chip stocks or the index, investors can get returns that comfortably beat inflation over the long term. However, creating massive wealth from the markets requires some risk-taking ability and a lot of patience.

News for Tilray Brands Stock (TLRY)